DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog

By
A A A

DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth quarter 2012 adjusted loss per share of 14 cents, better than the Zacks Consensus Estimate of a loss of 16 cents per share. For 2012, DexCom reported adjusted loss per share of 81 cents better than the Zacks Consensus Estimate of a loss of 84 cents per share. Net loss for the quarter dropped 30.3% year over year to $8.5 million (or loss of 12 cents per share).

Revenues

Revenues surged 48.7% year over year to $33.3 million in the fourth quarter, beating the Zacks Consensus Estimate of $29 million. For 2012, revenues rose 30.9% to $99.9 million surpassing the Zacks Consensus Estimate of $96 million. 

Product sales increased almost 51.7% to $31.7 million while development grant and other revenues improved 6.7% to $1.6 million in the reported quarter.

Margins and Expenses

Gross margin improved to 52.6% in the fourth quarter from 47.8% a year ago. Operating expenses increased 13.1% year over year to $25.9 million due to higher selling, general and administrative expenses, which grew 25.5% in the reported quarter. The company reduced its operating loss year over year.

Balance Sheet

DexCom exited the fourth quarter with cash and short-term marketable securities of $48.7 million, down 40.6% on a year-over-year basis. Long-term debt (net of current portion) amounted to $6.8 million, up from zero in the year-ago period.

Our Take

DexCom is well placed in the industry that it serves. Given the burgeoning diabetes population in the U.S., its G4 Platinum presents considerable market opportunity. Successful commercialization of G4 in the U.S. could just be the catalyst that the company needs to gain share in the market it serves.

Increased awareness and acceptance of the need for continuous glucose monitoring and international expansion should help drive sales of DexCom's products. The company is eyeing prospects in the vast markets of India, China and Japan.

In addition to upgrading and enhancing the functions of existing products, DexCom has also been active on the collaboration front, through which it is looking to leverage its technology with its collaborator's product offerings.

Competition in the glucose monitoring market is fierce. DexCom competes with Roche Diabetes Care, a division of Roche ( RHHBY ) and LifeScan under Johnson & Johnson ( JNJ ) for its Seven Plus offering. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems.

We believe that the company's move to buy healthcare IT company SweetSpot Diabetes Care, may allow it to compete more effectively through better data management systems.

Despite increasing revenues, DexCom remains a loss making entity and its efforts are made more difficult by a stringent regulatory environment. The stock currently holds a Zacks Rank #3 (Hold).



ABBOTT LABS (ABT): Free Stock Analysis Report

DEXCOM INC (DXCM): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

MEDTRONIC (MDT): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ABT , DXCM , JNJ , MDT , RHHBY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Quick on Your Feet
Quick on Your Feet                  
Early Entrepreneurship
Early Entrepreneurship              
Trying to Be Goofy
Trying to Be Goofy                  

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com